Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01461200
Recruitment Status : Completed
First Posted : October 28, 2011
Last Update Posted : March 27, 2014
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
The purpose of this study is to find out if the bacteria present in the nose or sinuses of people with seasonal allergies changes during their allergy season. Another purpose of this study is to see if the bacteria present in the nose and sinuses of non-allergic people are the same as allergic people before the allergy season and if it changes during the season. Many bacteria are difficult to grow in the laboratory so the investigators are using analysis of DNA (the genetic material in cells) of the bacteria in the nose and sinus to find them. The investigators will be testing DNA of the bacteria only and not of the human subjects taking part in this study. This research is being done to help us understand how allergy affects bacteria in the nose and sinuses.

Condition or disease Intervention/treatment
Allergic Rhinitis Other: Swab of vestibule and middle meatus of nose

Layout table for study information
Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Parallel Group Observational Study of the Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome
Study Start Date : March 2011
Actual Primary Completion Date : January 2012
Actual Study Completion Date : February 2012

Group/Cohort Intervention/treatment
Non allergics Other: Swab of vestibule and middle meatus of nose
Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season

allergics Other: Swab of vestibule and middle meatus of nose
Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season




Primary Outcome Measures :
  1. Change in bacterial profile of the sinuses [ Time Frame: Measured at baseline and 1 to 3 months later. ]
    DNA isolation to determine the bacterial profiles of samples taken at baseline (out of subjects' allergy season) and 1 to 3 months later during subjects' allergy season.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with seasonal allergies and healthy controls from the community.
Criteria

Inclusion Criteria

  1. Males and females between 18 and 55 years of age.
  2. History of tree and/or grass allergic rhinitis for at least 2 years (allergic subjects) or no allergy history at all (normal controls).
  3. For allergic subjects, a positive skin test to trees and/or grass antigen within prior 12 months. For non-allergic subjects, negative skin tests to common allergens in the Chicago area.

Exclusion Criteria

  1. Respiratory disease other than allergic rhinitis, allergic conjunctivitis and mild asthma.
  2. Use of nasal steroids, antihistamines in the last 4 weeks.
  3. Upper respiratory infection, sinusitis less than 2 weeks before screening.
  4. Structural nasal abnormalities or nasal polyps on examination, nasal ulcer, frequent nose bleeding, recent nasal surgery or nasal trauma (within 90 days).
  5. Participation in other investigational therapy in the last 30 days.
  6. Any systemic disorder or medication interfering with the study.
  7. Undergoing allergen desensitization therapy.
  8. Not willing to give informed consent
  9. Inability to understand the nature and requirements of the study, or to comply with the study procedures.
  10. Any social or medical condition that, in the opinion of the investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01461200


Locations
Layout table for location information
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Robert Naclerio, MD University of Chicago
Layout table for additonal information
Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT01461200    
Other Study ID Numbers: 10-712-A
First Posted: October 28, 2011    Key Record Dates
Last Update Posted: March 27, 2014
Last Verified: March 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases